Floatz logo

Panitumumab-Irdye800

Brain Cancer

Eben RosenthalEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Brain Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Davis
Phase 2BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Sorafenib
Virginia Commonwealth University
Phase 2BB
DIANHYDROGALACTITOL
Kintara Therapeutics, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Panitumumab-Irdye800 is also rated in:

pancreatic adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
meningiomaDormant
C
Indicative ·
39 / 100
View asset →
acoustic neuromaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →